<DOC>
	<DOCNO>NCT00459654</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness investigational radioisotope Radium-223 treatment men prostate cancer bone metastases long respond hormonal treatment .</brief_summary>
	<brief_title>A Placebo-controlled Phase II Study Bone-targeted Radium-223 Symptomatic Hormone-refractory Prostate Cancer</brief_title>
	<detailed_description>Primary objective : To study biological effectiveness radium-223 therapy measure : - Time occurrence skeletal-related event ( SREs ) - Change bone-specific alkaline phosphatase ( bone-ALP ) level Secondary objective : To study efficacy radium-223 therapy term : - Frequency new SREs - Proportions patient SRE - Proportions patient SRE different time point - Changes biochemical marker bone turnover - Treatment response regard pain analgesic use ( term `` Palliative effect '' study protocol ) - Quality life assessment - Overall survival To study safety repeat radium-223 regimen Total Enrollment:64 Study start : February 2004</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Histologically/cytologically confirm adenocarcinoma prostate Patient receive receive hormonal treatment ( orchiectomy , polyoestradiol phosphate , gonadotropinreleasing hormone analogue without antiandrogen ) Metastatic disease positive bone scan within 2 month treatment one cancer relate lesion one painful cancer relate lesion presence increase PSA level follow : PSA &gt; 5 ng/ml , increase least 2 successive occasion least 2 week apart . Patient refer local field radiotherapy ( EBR ) metastatic bone pain . The area treat ( index site ) match positive bone scan , local radiation area exceed 400 cm2 ECOG performance status : 02 Life expectancy : least 3 month Age 40 year Laboratory requirement : Hematology : Neutrophil count ≥1,5 x 109/L Platelet count least ≥100 x109/L stable Hemoglobin &gt; 100 g/l 10 g/dL Hepatic function : Bilirubin within normal institutional limit ASAT ALAT &lt; 2,5 time upper limit normal ( ULN ) Renal function : Creatinine &lt; 1,5 time ULN ( i.e . NCI grade ≤1 ) Patient willing able comply protocol , agree return hospital followup visit examination Patient fully inform study sign informed consent form Has receive investigational drug 4 week schedule receive one plan treatment period Has receive chemo , immunotherapy external radiotherapy within week study drug administration Has start treatment bisphosphonates within 3 month administration study drug . Has previously receive systemic radiotherapy strontium , samarium rhenium Change hormonal therapy within last 6 week study drug administration Other currently active ( relapse within last 3 year ) malignancy ( except nonmelanoma skin cancer ) know brain , liver , lung , visceral lymphatic metastasis dominate clinical picture patient Has receive blood transfusion within last month Other serious illness medical condition follow : uncontrolled infection heart insufficiency , grade 3 4 specify NCICTC criterion grade 2 great motor sensory neuropathy Crohn 's disease Ulcerative colitis 9 ) Known nonpathological bone fracture within last two month</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>HRPC</keyword>
	<keyword>Recurrent Prostate Cancer</keyword>
	<keyword>Metastatic Cancer</keyword>
</DOC>